Tag Archives: teva

December, 2018

October, 2018

September, 2018

August, 2018

January, 2018

October, 2017

September, 2017

August, 2017

  • 31 August

    FDA Approves Teva’s Austedo for Treatment of Tardive Dyskinesia in Adults

    JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a …

July, 2017

  • 31 July

    FDA to Review Teva and Celltrion’s BLA for Proposed Biosimilar to Herceptin

    INCHEON, Republic of Korea & JERUSALEM–(BUSINESS WIRE)–Jul. 31, 2017– Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P6, a proposed Monoclonal Antibody (mAb) biosimilar to Herceptin®1 (INN: trastuzumab) which is used for the treatment of Human Epidermal …